Phase I/II Trial: Sapanisertib (mTORC1/2 inhibitor) and cabozantinib in β-catenin–mutated metastatic liver cancer

This trial compares sapanisertib plus cabozantinib versus cabozantinib monotherapy, evaluating safety, dosing, and efficacy in metastatic hepatocellular carcinoma patients (including a β-catenin-mutated subgroup) to assess whether combination treatment offers improved outcomes; the study is sponsored by the National Cancer Institute.